# Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

> **NCT05633615** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 396 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Grade 3b Follicular Lymphoma
- Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Transformed Follic Lymph to Diff Large B-Cell Lymphoma
- Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Lisocabtagene Maraleucel
- **BIOLOGICAL:** Mosunetuzumab
- **OTHER:** Patient Observation
- **DRUG:** Polatuzumab Vedotin
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Tisagenlecleucel

## Key facts

- **NCT ID:** NCT05633615
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633615, "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05633615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*